GO:0045668 negative regulation of osteoblast differentiation: Molecular Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045668 (negative regulation of osteoblast differentiation) describes any process that stops, prevents, or reduces the frequency, rate or extent of osteoblast differentiation, the lineage commitment step that produces bone-forming cells.
• The term is a biological_process branch of the Gene Ontology and is the conceptual opposite of positive regulation of osteoblast differentiation (GO:0045669).
• Core molecular brakes include transcription-factor inhibitors such as Atf7ip, which represses Sp7 (Osterix), and Runx2, the master inducer whose activity must be tightly restrained for balanced bone formation.
• Extracellular and metabolic inputs, including sclerostin signaling from osteocytes, nitric oxide-dependent glycolysis, and inflammasome-linked inflammatory tone, all feed into negative regulation of osteoblast differentiation.
• Dysregulation of this process contributes to osteoarthritis, where single-cell transcriptomics has resolved distinct osteoblast subtypes, and to impaired osteogenesis in senescent pre-osteoblast populations.
• CRISPR knockout, point-mutation, knock-in, and overexpression models, combined with CRISPR library screening and bioinformatics, are the standard toolkit for dissecting negative regulators of osteoblast differentiation.
Description
Osteoblast differentiation is the developmental program by which mesenchymal progenitors commit to and mature into bone-forming osteoblasts. Because bone mass is determined by the balance between osteoblast-mediated formation and osteoclast-mediated resorption, the negative regulation of osteoblast differentiation (GO:0045668) is as important as its positive counterpart. The Gene Ontology defines this term as any process that stops, prevents, or reduces the frequency, rate or extent of osteoblast differentiation, and it is annotated as a biological_process. In practical terms, GO:0045668 collects the molecular brakes, checkpoints, and inhibitory signals that keep osteoblast commitment in check. Researchers care about GO:0045668 because excessive or inappropriate inhibition of osteoblast differentiation underlies bone-loss phenotypes, delayed fracture healing, and degenerative joint disease. For example, single-cell transcriptomics of knee osteoarthritis has revealed novel chondrocyte and osteoblast subtypes whose altered differentiation states contribute to pathogenesis. At the molecular level, factors such as Atf7ip directly inhibit osteoblast differentiation by negatively regulating the Sp7 transcription factor, while Runx2, the master inducer of osteoblast and chondrocyte differentiation, must itself be restrained to avoid pathological outcomes. Beyond transcription factors, the term encompasses metabolic and extracellular control. Nitric oxide modulates bone anabolism by regulating osteoblast glycolysis and differentiation, sclerostin antibody conjugated surfaces alter osteocyte-mediated regulation of osteoblast differentiation, and anacardic acid-mediated regulation of osteoblast differentiation involves mitigation of inflammasome activation pathways. Senescent pre-osteoblast cells induced by hydrogen peroxide show altered osteogenic differentiation linked to METTL3/YTHDF2-dependent control of LINC01013. Together these studies illustrate that negative regulation of osteoblast differentiation is a multi-layered process integrating transcriptional, epigenetic, metabolic, and inflammatory inputs.
negative regulation of osteoblast differentiation At A Glance
| GO ID | GO:0045668 |
|---|---|
| GO term | negative regulation of osteoblast differentiation |
| Ontology | biological_process |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of osteoblast differentiation. |
| Synonym | down regulation of osteoblast differentiation; down-regulation of osteoblast differentiation; downregulation of osteoblast differentiation; inhibition of osteoblast differentiation |
| Major function | Restrains the commitment and maturation of osteoprogenitors into bone-forming osteoblasts, balancing bone formation. |
| Opposite term | positive regulation of osteoblast differentiation (GO:0045669) |
| Related cell type | Osteoblast, osteoprogenitor, osteocyte |
| Related process | Osteoblast differentiation (GO:0001649), bone mineralization, skeletal development |
What Is GO:0045668?
GO:0045668, negative regulation of osteoblast differentiation, is a Gene Ontology biological_process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of osteoblast differentiation. In other words, it is the collection of cellular and molecular events that act as brakes on the developmental program converting osteoprogenitors into mature bone-forming osteoblasts. The term is a negative regulatory node: it does not describe the differentiation program itself but the inhibitory inputs that modulate it. Its synonyms include down regulation of osteoblast differentiation, down-regulation of osteoblast differentiation, downregulation of osteoblast differentiation, and inhibition of osteoblast differentiation.
Why Is negative regulation of osteoblast differentiation Important in Cell Biology?
Negative regulation of osteoblast differentiation is central to skeletal homeostasis because bone mass reflects the balance between osteoblast-driven formation and osteoclast-driven resorption. When inhibitory inputs are too strong, osteoblast numbers and activity fall, tipping the balance toward bone loss and degenerative disease. Conversely, loss of these brakes can drive excessive or ectopic bone formation. Understanding GO:0045668 therefore informs therapeutic strategies for osteoporosis, osteoarthritis, fracture repair, and bone-related metabolic disorders, and it provides a mechanistic framework for interpreting how inflammatory, metabolic, and epigenetic signals converge on the osteoblast lineage.
• Controls bone mass by limiting the number and activity of bone-forming osteoblasts.
• Provides the mechanistic counterweight to Runx2-driven osteoblast commitment.
• Links inflammatory signaling, including inflammasome activation, to impaired osteogenesis.
• Connects metabolic regulation, such as nitric oxide-dependent glycolysis, to bone anabolism.
• Involves osteocyte-derived signals such as sclerostin that suppress osteoblast differentiation.
• Is dysregulated in osteoarthritis, where distinct osteoblast subtypes contribute to pathogenesis.
• Is altered in senescent pre-osteoblast populations relevant to aging bone.
• Offers druggable nodes for anabolic bone therapies and for modulating fracture healing.
• Serves as a functional annotation hub for interpreting CRISPR screens and transcriptomic data.
• Helps explain cell-shape, cytoskeletal, and RhoA-dependent lineage commitment decisions.
What Happens During negative regulation of osteoblast differentiation?
Transcriptional Brakes on the Osteoblast Program
In simple terms: Certain proteins act as switches that turn down the genes needed to make bone-forming cells.
The osteoblast differentiation program is driven by master transcription factors such as Runx2, which induces both osteoblast and chondrocyte differentiation. Negative regulation of osteoblast differentiation frequently operates by restraining these drivers. Atf7ip, for example, inhibits osteoblast differentiation via negative regulation of the Sp7 transcription factor, directly suppressing a key osteoblast commitment factor. This layer of control ensures that progenitor cells do not commit prematurely or excessively, and it provides a transcriptional checkpoint that can be modulated by upstream signals.
Epigenetic and RNA-Level Control
In simple terms: Chemical marks on DNA-associated proteins and RNA molecules can silence or destabilize messages that promote bone cell formation.
Epigenetic and post-transcriptional mechanisms contribute to negative regulation of osteoblast differentiation. In senescent pre-osteoblast cells induced by hydrogen peroxide, the m6A reader YTHDF2 and the methyltransferase METTL3 negatively regulate the long non-coding RNA LINC01013, and this axis enhances osteogenic differentiation when LINC01013 is suppressed. This illustrates how RNA modification and non-coding RNA turnover can act as brakes or accelerators within the osteoblast lineage, and it highlights the interplay between cellular senescence and osteogenic capacity.
Metabolic and Redox Inputs
In simple terms: How a cell uses energy and handles reactive molecules can decide whether it becomes a bone-forming cell.
Metabolic state is a recognized modulator of osteoblast differentiation. Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation, linking redox signaling to the metabolic program required for osteoblast function. Inflammatory and redox stress also intersect with this process: anacardic acid-mediated regulation of osteoblast differentiation involves mitigation of inflammasome activation pathways, indicating that inflammatory tone can suppress osteogenic commitment. These findings position metabolism and inflammation as upstream inputs that can enforce negative regulation of osteoblast differentiation.
Extracellular and Osteocyte-Derived Signals
In simple terms: Mature bone cells send out signals that tell younger cells to slow down bone formation.
Osteocytes, the terminally differentiated cells embedded in bone matrix, regulate osteoblast differentiation through secreted factors. Osteocytes cultured on sclerostin antibody conjugated TiO2 nanotube arrays modulate osteoblast differentiation, demonstrating that neutralizing sclerostin alters the inhibitory signal that osteocytes normally provide. This extracellular control loop is a major mechanism by which negative regulation of osteoblast differentiation is achieved in vivo, and it is a validated therapeutic target for anabolic bone agents.
Mechanotransduction and Cytoskeletal Tension
In simple terms: The physical shape and stiffness a cell feels can push it toward or away from becoming a bone cell.
Cell shape, cytoskeletal tension, and RhoA signaling regulate stem cell lineage commitment, including the choice between osteogenic and adipogenic fates. Mechanical cues therefore act as a higher-order negative or positive regulatory input on osteoblast differentiation. When cytoskeletal tension is low, commitment to the osteoblast lineage can be reduced, effectively contributing to negative regulation of osteoblast differentiation. This mechanotransduction layer integrates with transcriptional and metabolic controls described above.
Key Genes Involved in GO:0045668 negative regulation of osteoblast differentiation
The following genes and proteins have been experimentally implicated in negative regulation of osteoblast differentiation or in the regulatory circuits that control it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATF7IP | Inhibits osteoblast differentiation via negative regulation of Sp7 | Direct transcriptional brake; knockout and overexpression models test causality |
| SP7 (Osterix) | Master osteoblast transcription factor targeted by Atf7ip | Readout of inhibitory tone; point mutations affect DNA binding |
| RUNX2 | Master inducer of osteoblast and chondrocyte differentiation | Central node whose restraint defines negative regulation |
| SOST (Sclerostin) | Osteocyte-derived inhibitor of osteoblast differentiation | Antibody neutralization modulates osteoblast differentiation in culture |
| METTL3 | m6A methyltransferase regulating LINC01013 stability | Epigenetic control in senescent pre-osteoblasts |
| YTHDF2 | m6A reader mediating LINC01013 degradation | Post-transcriptional brake in osteogenic differentiation |
| LINC01013 | Long non-coding RNA negatively regulated by METTL3/YTHDF2 | Modulates osteogenic differentiation of senescent cells |
| NOS / nitric oxide pathway | Regulates osteoblast glycolysis and differentiation | Metabolic control of bone anabolism |
| Inflammasome components (e.g., NLRP3 axis) | Inflammatory signaling mitigated by anacardic acid | Links inflammation to suppressed osteoblast differentiation |
| RHOA | Cytoskeletal tension regulator of lineage commitment | Mechanotransduction input into osteoblast fate |
| Osteoblast subtypes (single-cell defined) | Distinct osteoblast populations in osteoarthritis | Single-cell transcriptomics identifies pathogenic subtypes |
| Senescent pre-osteoblast markers | Cellular senescence alters osteogenic capacity | Hydrogen peroxide-induced senescence model |
| Sclerostin antibody targets | Neutralizes osteocyte inhibitory signals | TiO2 nanotube array culture platform |
| Glycolysis enzymes | Support osteoblast metabolic program | Nitric oxide-dependent regulation |
| Inflammatory cytokines | Suppress osteogenic commitment | Anacardic acid mitigation of inflammasome pathways |
How Is negative regulation of osteoblast differentiation Regulated?
Negative regulation of osteoblast differentiation is itself regulated at multiple levels. Transcriptionally, factors such as Atf7ip restrain Sp7 activity, providing a direct brake on the osteoblast program. Epigenetically, METTL3 and YTHDF2 control the stability of LINC01013, thereby tuning osteogenic differentiation in senescent pre-osteoblasts. Metabolically, nitric oxide modulates osteoblast glycolysis and differentiation, linking energy metabolism to the differentiation decision. Inflammatory signaling through inflammasome activation pathways can suppress osteoblast differentiation, and this suppression is mitigated by anacardic acid. Extracellularly, osteocyte-derived sclerostin provides a tonic inhibitory signal that can be neutralized by sclerostin antibodies. Finally, mechanotransduction through RhoA and cytoskeletal tension influences lineage commitment, adding a physical dimension to the regulation of osteoblast differentiation. Together, these layers form a regulatory network in which negative regulation of osteoblast differentiation integrates transcriptional, epigenetic, metabolic, inflammatory, and mechanical inputs.
negative regulation of osteoblast differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATF7IP | Osteoblast differentiation inhibition | Knockout and overexpression in osteoprogenitor cells |
| SOST | Osteocyte-mediated suppression of bone formation | Sclerostin antibody treatment in osteocyte-osteoblast co-culture |
| METTL3 | Senescence-associated osteogenic impairment | Hydrogen peroxide-induced senescent pre-osteoblast model |
| LINC01013 | Osteogenic differentiation in aging | Knockdown and overexpression in senescent pre-osteoblasts |
| RUNX2 | Skeletal development and osteoarthritis | Point-mutation and knock-in models of Runx2 activity |
Osteoarthritis and Degenerative Joint Disease
Single-cell transcriptomics of knee osteoarthritis has revealed novel chondrocyte and osteoblast subtypes and their role in pathogenesis, indicating that altered osteoblast differentiation states contribute to degenerative joint disease. Negative regulation of osteoblast differentiation is therefore relevant to understanding why osteophyte formation and subchondral bone changes occur in osteoarthritis. Experimental models that manipulate inhibitory nodes, such as Atf7ip or sclerostin signaling, can help dissect whether restoring or enhancing osteoblast differentiation ameliorates or exacerbates joint pathology.
Aging Bone and Senescence
Cellular senescence impairs the osteogenic capacity of pre-osteoblast cells. In hydrogen peroxide-induced senescent pre-osteoblast cells, the METTL3/YTHDF2/LINC01013 axis regulates osteogenic differentiation, linking RNA modification and senescence to negative regulation of osteoblast differentiation. This has implications for age-related bone loss and for understanding why bone formation declines with age. Targeting this axis could potentially restore osteogenic potential in senescent populations.
Inflammatory Bone Loss
Inflammatory signaling can suppress osteoblast differentiation, and anacardic acid-mediated regulation of osteoblast differentiation involves mitigation of inflammasome activation pathways. This connects negative regulation of osteoblast differentiation to inflammatory bone diseases and suggests that anti-inflammatory strategies may indirectly promote osteogenesis. The interplay between inflammasome activity and osteoblast commitment is an active area of research relevant to periodontitis, rheumatoid arthritis, and other inflammatory bone conditions.
Metabolic Bone Disease
Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation, indicating that metabolic dysregulation can alter the balance of bone formation. Conditions characterized by altered nitric oxide signaling or glycolytic capacity may therefore exhibit changes in negative regulation of osteoblast differentiation. This provides a rationale for studying metabolic interventions in bone disease models.
From negative regulation of osteoblast differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene a causal brake on osteoblast differentiation? | CRISPR knockout in osteoprogenitor cell line or primary mesenchymal stem cells |
| Does a specific amino acid change alter inhibitory activity? | Point-mutation knock-in using CRISPR base editing or HDR |
| Does a disease-associated variant affect osteoblast differentiation? | Knock-in of the variant allele followed by osteogenic differentiation assays |
| Where and when is the negative regulator expressed? | Tagged knock-in with fluorescent or epitope tag for imaging and ChIP |
| Does overexpression of a candidate gene suppress osteogenesis? | Doxycycline-inducible overexpression in osteoblast precursors |
| Which pathways cooperate with a known brake? | CRISPR library screening combined with bioinformatics analysis |
How to Study the negative regulation of osteoblast differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify inhibitory genes during osteoblast differentiation |
| Single-cell RNA-seq | Cell-type and subtype heterogeneity | Resolve osteoblast subtypes in osteoarthritis |
| MeRIP-seq | m6A RNA modification sites | Study METTL3/YTHDF2 regulation of LINC01013 |
| Seahorse assay | Glycolytic and oxidative metabolism | Assess nitric oxide effects on osteoblast glycolysis |
| Inflammasome activity assays | Caspase-1 and cytokine output | Test anacardic acid mitigation of inflammasome pathways |
| Micropatterning and traction force microscopy | Cell shape and cytoskeletal tension | Study RhoA-dependent lineage commitment |
| Sclerostin antibody functional assays | Osteocyte-mediated inhibition | Evaluate sclerostin neutralization on osteoblast differentiation |
| CRISPR library screening | Gene essentiality and pathway interactions | Discover novel negative regulators of osteoblast differentiation |
Transcriptomic and Single-Cell Approaches
RNA sequencing and single-cell transcriptomics are powerful for resolving osteoblast subtypes and their differentiation states. Single-cell transcriptomics has been used to identify novel chondrocyte and osteoblast subtypes in knee osteoarthritis, providing a map of differentiation states relevant to negative regulation of osteoblast differentiation. These methods allow researchers to quantify expression of inhibitory factors such as ATF7IP, METTL3, and YTHDF2 across differentiation trajectories.
Epigenetic and RNA Modification Assays
Because m6A modification and non-coding RNAs contribute to negative regulation of osteoblast differentiation, methods such as MeRIP-seq, RNA immunoprecipitation, and RNA stability assays are valuable. The METTL3/YTHDF2/LINC01013 axis was dissected using such approaches in senescent pre-osteoblast cells. These techniques reveal how RNA-level control modulates osteogenic commitment.
Metabolic and Signaling Assays
Measuring glycolysis, nitric oxide production, and inflammasome activation helps link metabolism and inflammation to negative regulation of osteoblast differentiation. Nitric oxide-dependent regulation of osteoblast glycolysis and differentiation can be assessed using Seahorse extracellular flux analysis and nitric oxide donors or inhibitors. Inflammasome activation pathways can be monitored by cytokine profiling and caspase-1 activity assays in the presence of modulators such as anacardic acid.
Imaging and Mechanobiology
Cell shape, cytoskeletal tension, and RhoA activity influence lineage commitment, so imaging-based approaches are essential. Micropatterned substrates and traction force microscopy have been used to show that cell shape and cytoskeletal tension regulate stem cell lineage commitment. These methods can be combined with osteogenic differentiation markers to study how mechanical inputs contribute to negative regulation of osteoblast differentiation.
How CRISPR Can Be Used to Study GO:0045668 negative regulation of osteoblast differentiation
Knockout
CRISPR knockout is used to remove candidate negative regulators and test whether loss of function enhances osteoblast differentiation. For example, knocking out ATF7IP would be expected to relieve repression of Sp7 and promote osteoblast differentiation, a hypothesis directly testable in osteoprogenitor cells. Knockout of METTL3 or YTHDF2 can reveal their roles in the m6A-dependent control of LINC01013 and osteogenic differentiation. Knockout studies provide causal evidence that a gene functions within GO:0045668.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair allow fine mapping of functional domains. For transcription factors such as Runx2, point mutations can dissect DNA-binding or protein-interaction surfaces that mediate negative regulation. Similarly, point mutations in Sp7 that alter its susceptibility to Atf7ip-mediated inhibition can be modeled to understand the molecular interface. These models are valuable when complete knockout is lethal or confounds interpretation.
Knock-in
Knock-in strategies enable tagging of endogenous proteins with fluorescent or epitope tags to track localization, stability, and interactions. Tagged knock-in of ATF7IP or SP7 allows imaging of their dynamic interplay during osteoblast differentiation. Knock-in of disease-associated variants in genes such as RUNX2 can model how specific alleles alter the balance of negative regulation. Knock-in reporter lines also permit live tracking of osteoblast differentiation states.
Overexpression
Overexpression models test whether increased dosage of a candidate gene is sufficient to suppress osteoblast differentiation. Inducible overexpression of ATF7IP or LINC01013 can be used to determine whether these factors are sufficient to inhibit osteogenesis. Overexpression of constitutively active RhoA can mimic high cytoskeletal tension states and alter lineage commitment. These models complement loss-of-function studies to establish sufficiency within GO:0045668.
How EDITGENE Supports negative regulation of osteoblast differentiation Research
Researchers studying negative regulation of osteoblast differentiation-related genes often need to determine whether a candidate gene is causally involved in restraining osteoblast commitment, and whether that activity can be modulated for therapeutic benefit. Establishing causality requires precise genetic models that isolate loss-of-function, gain-of-function, and variant-specific effects in relevant osteoprogenitor or mesenchymal stem cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of osteoblast differentiation research.
Frequently Asked Questions About negative regulation of osteoblast differentiation
What is negative regulation of osteoblast differentiation (GO:0045668)?
GO:0045668 is a Gene Ontology biological_process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of osteoblast differentiation, the developmental program that produces bone-forming osteoblasts.
What genes are involved in negative regulation of osteoblast differentiation?
Key genes include ATF7IP, which inhibits osteoblast differentiation via negative regulation of Sp7, RUNX2, the master inducer whose activity is restrained, METTL3 and YTHDF2, which control LINC01013 stability, and SOST (sclerostin), an osteocyte-derived inhibitor.
How does Atf7ip inhibit osteoblast differentiation?
Atf7ip inhibits osteoblast differentiation through negative regulation of the Sp7 transcription factor, directly suppressing a key osteoblast commitment factor.
What is the role of Runx2 in osteoblast differentiation?
Runx2 is an inducer of osteoblast and chondrocyte differentiation, and its activity must be tightly regulated to balance bone formation.
How does nitric oxide affect osteoblast differentiation?
Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation, linking metabolic signaling to osteoblast function.
What is the connection between osteoarthritis and osteoblast differentiation?
Single-cell transcriptomics has revealed novel chondrocyte and osteoblast subtypes and their role in knee osteoarthritis pathogenesis, indicating that altered osteoblast differentiation contributes to disease.
How is sclerostin involved in osteoblast differentiation?
Osteocytes cultured on sclerostin antibody conjugated TiO2 nanotube arrays regulate osteoblast differentiation, showing that neutralizing sclerostin alters osteocyte-mediated inhibition.
What role does METTL3 play in osteoblast differentiation?
METTL3, together with YTHDF2, negatively regulates LINC01013, and this axis enhances osteogenic differentiation of senescent pre-osteoblast cells when LINC01013 is suppressed.
How can CRISPR be used to study negative regulation of osteoblast differentiation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes, while CRISPR library screening enables unbiased discovery of negative regulators.
What experimental models are used to study GO:0045668?
Common models include osteoprogenitor cell lines, primary mesenchymal stem cells, senescent pre-osteoblast models induced by hydrogen peroxide, and osteocyte-osteoblast co-culture systems with sclerostin antibody treatment.
Conclusion
Negative regulation of osteoblast differentiation (GO:0045668) is a central biological_process that restrains the commitment and maturation of bone-forming osteoblasts. It integrates transcriptional brakes such as Atf7ip-mediated inhibition of Sp7, epigenetic and RNA-level control through METTL3/YTHDF2 and LINC01013, metabolic inputs from nitric oxide signaling, inflammatory modulation via inflammasome pathways, and extracellular cues from osteocyte-derived sclerostin. Dysregulation of this process is implicated in osteoarthritis, aging-related bone loss, and inflammatory bone disease. Understanding GO:0045668 requires precise genetic models to establish causality. CRISPR knockout, point-mutation, knock-in, and overexpression approaches, combined with CRISPR library screening and bioinformatics, provide the toolkit needed to dissect these regulatory networks. EDITGENE supports researchers in building these models to accelerate discovery of therapeutic targets that modulate osteoblast differentiation.
References
- 1. Hu G et al.. 2023. Atf7ip Inhibits Osteoblast Differentiation via Negative Regulation of the Sp7 Transcription Factor.. Int J Mol Sci 24(5) PMID: 36901736
- 2. Liu Y et al.. 2025. Single-cell transcriptomics reveals novel chondrocyte and osteoblast subtypes and their role in knee osteoarthritis pathogenesis.. Signal Transduct Target Ther 10(1):40 PMID: 39904988
- 3. Venugopal M et al.. 2021. Anacardic acid-mediated regulation of osteoblast differentiation involves mitigation of inflammasome activation pathways.. Mol Cell Biochem 476(2):819-829 PMID: 33090336
- 4. Chen M et al.. 2019. Regulation of osteoblast differentiation by osteocytes cultured on sclerostin antibody conjugated TiO(2) nanotube array.. Colloids Surf B Biointerfaces 175:663-670 PMID: 30590327
- 5. Jin Z et al.. 2021. Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation.. J Clin Invest 131(5) PMID: 33373331
- 6. Song J et al.. 2024. Negative Regulation of LINC01013 by METTL3 and YTHDF2 Enhances the Osteogenic Differentiation of Senescent Pre-Osteoblast Cells Induced by Hydrogen Peroxide.. Adv Biol (Weinh) 8(5):e2300642 PMID: 38548669
- 7. Komori T. 2018. Runx2, an inducer of osteoblast and chondrocyte differentiation.. Histochem Cell Biol 149(4):313-323 PMID: 29356961
- 8. McBeath R et al.. 2004. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment.. Dev Cell 6(4):483-95 PMID: 15068789
